Mickaël Hiligsmann (M.J.C.)

Agh, T., Borah, B., Vervloet, M., & Hiligsmann, M. (2026). Medication adherence research: expert perspectives on key HEOR trends for 2026. Expert Review of Pharmacoeconomics & Outcomes Research, 1-3. https://doi.org/10.1080/14737167.2026.2650160

Chandran, M., Reginster, J.-Y., Kim, M.-Y., & Hiligsmann, M. (2026). Clinical and economic impact of deep learning-enhanced opportunistic osteoporosis screening using chest radiographs with and without the osteoporosis self-assessment tool for Asians (OSTA). Osteoporosis International, 37(3), 717-726. https://doi.org/10.1007/s00198-026-07858-1

Dalhuisen, I., Wurkum, M., Bervoets, C., Constant, E., van Exel, E., Hiligsmann, M., Sack, A., Schuhmann, T., Tendolkar, I., Verplancke, T., Wijnen, B., Baeken, C., & van Eijndhoven, P. (2026). Enhancing effect of cognitive control training on rTMS treatment in depression: A study protocol for a multicenter randomized controlled trial. Contemporary Clinical Trials, 161, Article 108212. https://doi.org/10.1016/j.cct.2025.108212

Hiligsmann, M., Kong, S. H., Alokail, M., Kim, M.-Y., & Reginster, J.-Y. (2026). Evaluating the cost-effectiveness of artificial intelligence-enhanced osteoporosis screening in men and women using routine chest radiographs in South Korea. JBMR plus, 10(2), Article ziaf187. https://doi.org/10.1093/jbmrpl/ziaf187

Wiethoff, I., Witlox, W. J. A., Evers, S. M. A. A., Michels, M., & Hiligsmann, M. (2026). Model-Based Economic Evaluation of the First-in-Class Myosin Inhibitor Mavacamten Versus Care as Usual in Obstructive Hypertrophic Cardiomyopathy Patients from a Dutch Societal Perspective. Pharmacoeconomics, 44(2), 245-259. https://doi.org/10.1007/s40273-025-01564-2

Maas, L., Contreras-Meca, C., Ghezzo, S., Belmans, F., Corsi, A., Cant, J., Vos, W., Bobowicz, M., Rygusik, M., Wysocki, P. T., Weiss, M. E. R., Neri, E., Caputo, F. P., Franceschello, R., Fanni, S. C., Annemans, L., & Hiligsmann, M. (2026). Cost-effectiveness analysis of artificial intelligence (AI) for response prediction of neoadjuvant radio(chemo)therapy in locally advanced rectal cancer (LARC) in the Netherlands. Expert Review of Pharmacoeconomics & Outcomes Research, 26(2), 303-312. https://doi.org/10.1080/14737167.2026.2615683

Li, N., Rambod, B., Dukers-Muijrers, N., Chevalier, J. M., Steijvers, L., Kojan, L., Wijnen, S., Crutzen, R., Jahn, B., Siebert, U., Stellbrink, L., Van Daalen, F., Kretzschmar, M., & Hiligsmann, M. (2026). General population preferences for health-related protective behaviors during infectious disease emergencies: a systematic review of conjoint-analysis studies. Social Science & Medicine, 388, Article 118721. https://doi.org/10.1016/j.socscimed.2025.118721

Iskandar, K., Roques, C., Salameh, P., Rizk, R., Daham, J., Hiligsmann, M., Karam, R., & Molinier, L. (2026). Economics perspectives on understanding antimicrobial use and resistance: a scoping review from theory to practice. Expert Review of Pharmacoeconomics & Outcomes Research, 26(1), 33-52. https://doi.org/10.1080/14737167.2025.2591291

Heinz, K. C., Beaudart, C., De Greef, A., Vanhooteghem, O., Gostynski, A., & Hiligsmann, M. (2026). Patients' preferences for atopic dermatitis treatments in Europe: a discrete choice experiment. Expert Review of Pharmacoeconomics & Outcomes Research, 26(1), 131-138. https://doi.org/10.1080/14737167.2025.2594633

Maas, L., Yaylali, A., & Hiligsmann, M. (2026). Prevention, artificial intelligence, and mathematics in health economics: a framework for dynamic value modeling under long-term uncertainty. Expert Review of Pharmacoeconomics & Outcomes Research. Advance online publication. https://doi.org/10.1080/14737167.2026.2642648